溶瘤单纯疱疹病毒1型联合来那度胺治疗浆细胞肿瘤
本研究探讨第三代溶瘤单纯疱疹病毒1型T-01对骨髓瘤细胞的直接溶瘤作用及免疫激活机制,并评估其与来那度胺联合的效应。体外实验显示T-01对6株人骨髓瘤细胞系中的5株有直接溶瘤作用,且该作用在健康供者外周血单个核细胞存在时增强,其增强效应依赖于pDC来源的I型干扰素和NK细胞。T-01与来那度胺联合 exhibit 增强的细胞毒性,三联联合T-01、来那度胺和IFN-α效果最大。
要点
- T-01对5/6株人骨髓瘤细胞系有直接溶瘤作用。
- PBMCs增强T-01抗肿瘤效应,依赖pDC来源I型IFN和NK细胞。
- T-01联合来那度胺及IFN-α展现最大细胞毒性。
核心结论
- 溶瘤HSV-1通过直接溶瘤和pDC/NK细胞介导的免疫激活对浆细胞肿瘤具有治疗潜力。
- 来那度胺可能增强HSV-1的抗骨髓瘤效应。
研究设计与样本
- 体外研究,使用6株人骨髓瘤细胞系及健康个体和骨髓瘤患者的外周血单个核细胞。
主要发现
- T-01对6株人骨髓瘤细胞系中的5株有直接溶瘤作用。
- 健康个体PBMCs增强T-01抗肿瘤效应,骨髓瘤患者PBMCs增强程度较低。
- 阻断I型IFNs或去除pDCs或NK细胞可消除PBMCs的增强效应。
- T-01与来那度胺联合显示增强的细胞毒性,三联联合T-01、来那度胺和IFN-α效果最大。
临床怎么用
- 提示溶瘤HSV-1联合来那度胺可能作为浆细胞肿瘤的治疗策略,但需进一步临床验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Oncolytic viruses exert an anti-tumour effect through two mechanisms: direct oncolytic and indirect immune-mediated mechanisms. Although oncolytic herpes simplex virus type 1 (HSV-1) has been approved for melanoma treatment and is being examined for its applicability to a broad spectrum of malignancies, it is not known whether it has an anti-myeloma effect. In the present study, we show that the third-generation oncolytic HSV-1, T-01, had a direct oncolytic effect on five of six human myeloma cell lines in vitro. The anti-tumour effect was enhanced in the presence of peripheral blood mononuclear cells (PBMCs) from healthy individuals and, to a lesser extent, from patients with myeloma. The enhancing effect of PBMCs was abrogated by blocking type I interferons (IFNs) or by depleting plasmacytoid dendritic cells (pDCs) or natural killer (NK) cells, suggesting that pDC-derived type I IFNs and NK cells dominated the anti-tumour effect. Furthermore, the combination of T-01 and lenalidomide exhibited enhanced cytotoxicity, and the triple combination of T-01, lenalidomide and IFN-α had a maximal effect. These data indicate that oncolytic HSV-1 represents a viable therapy for plasma cell neoplasms through direct oncolysis and immune activation governed by pDCs and NK cells. Lenalidomide is likely to augment the anti-myeloma effect of HSV-1.
引用
- Oku M, Ishino R, Uchida S, et al. Oncolytic herpes simplex virus type 1 (HSV-1) in combination with lenalidomide for plasma cell neoplasms. Br J Haematol. 2020. PMID: 33216988. doi:10.1111/bjh.17173
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。